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The ultimate goal of periodontal ther-
apy has always been the regeneration
of the lost periodontal supporting
structures. Several methods have been
employed over time to achieve this
goal. Guided tissue regeneration
(GTR) using bone grafts, barrier
membranes or a combination of both
has been the most commonly used
approach. The results obtained from
these treatments have been shown to
be superior to open flap debridement
(1–4). However, GTR has been proven
to be very technique sensitive and the
results achieved were often unpredict-
able (4). This can be attributed by
frequent exposure (4) of the implanted
materials to the oral cavity and many
other factors such as interproximal
bone level, defect morphology, wound
control, smoking habit and poor oral
hygiene (5–10). Consequently, a search
began for second-generation regenera-
tive agents. Among these agents,
EMDs have become the first bioactive
agent to be used in periodontal clinical
practice. The commercially available
product is called Emdogain (Strauman
international, Basel, Switzerland).
EMD is obtained from developing
teeth germs of 6-mo-old piglets (11)
and is believed to participate in the
development of periodontal supporting
structures during tooth-formation
processes (12) such as amelogenesis
(13). Furthermore, EMD can also exert
effects on cell attachment, spreading,
chemotaxis, proliferation and cell sur-
vival (14). Moreover, EMD has the
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regards to the clinical effectiveness of EMD in treating periodontal infrabony
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capacity to express growth factors,
cytokines and extracellular matrix
components, as well as molecules per-
tinent to osteogenesis and osteoclasto-
genesis (14). Lastly, EMD possesses
antibacterial function which is largely
attributed to its vehicle, propylene
glycol alginate (14,15). EMD has also
been shown to enhance periodontal
regeneration after surgery (11), to
improve treatment results in intrabony
and mandibular Class II furcation
defects (2), to minimize postsurgical
complications when used as an alter-
native to GTR barrier membrane (16)
and to aid soft tissue root-coverage
procedures (17).
Generally, studies published around
the time that a product is launched often
report favorable clinical outcomes
(18–20). However, a recent publication
documented inferior results of EMD in
noncontained defects when compared
with GTR (21). Hence, the aim of this
meta-analysis was to determine any
differences between the results of early
studies and late studies results when
EMD was used as an adjunct to treat
human intrabony defects during flap
surgery.
Material and methods
PubMed and MEDLINE searches
were performed for the period January
1997 to July 2010. Articles included
were clinical trials in which EMD was
used for the treatment of intrabony
defects. The search used the medical
subject heading (MeSH) terms Emdo-
gain, enamel matrix derivatives,
enamel matrix proteins, dental enamel
proteins, periodontal intrabony defects
and biologic agents. Inclusion criteria
included English language publications
of human clinical trials (randomized
clinical trials, case–control studies and
case series). Clinical outcomes such as
clinical attachment level (CAL) gains,
probing pocket depth reductions and
bone gain (BG) were documented.
Studies were then divided into two
evaluation time-periods: 1997–2003
and 2004–2010. Moreover, studies
limited to the use of EMD alone or in
which at least one arm of the study
evaluated EMD alone for regeneration
of intrabony defects were included in
this meta-analysis. Furthermore, each
evaluation period was divided accord-
ing to the available outcome measures:
probing pocket depth reduction (in
mm), CAL gain (in mm) and BG (in
mm, or as a percentage if available).
Lastly, the standard deviation of each
individual parameter had to be
reported, in order to facilitate statisti-
cal analysis. In total, 76 studies were
screened and, of these, 39 met the
inclusion criteria. Studies were
excluded if they did not report the
clinical parameters listed above, if no
standard deviations were present, if no
full-text reports were retrievable or if
no treatment with EMD alone was
evaluated.
Twenty early studies (carried out in
the time-period from 1997 to 2003) met
the inclusion criteria (18–20,22–38). A
total of 11 studies reported BG after
treatment with EMD: four reported BG
in both mm and as a percentage
(14,18,19,24,37); five studies reported
BG in mm (22,27,28,31,36); and only
two reported BG as a percentage
(25,26). Eighteen late studies (carried
out in the time-period 2004–2010) met
the inclusion criteria (16,21,27,39–53).
A total of nine studies evaluated BG:
three reported BG in both mm and as a
percentage (41–43,53); five reported BG
in mm only (44,46,50,52,53); and one
study reported bone gain only as a per-
centage (48) (Tables 1A,B).
The statistical analysis was per-
formed by the Center for Statistical
Consultation and Research at the
University of Michigan. We used a
random-effects meta-analysis to com-
bine information from the 39 studies
included in this meta-analysis, strati-
fied by group (early studies vs. late
studies). A random-effects meta-
regression was used to compare the
effect of each outcome variable for
early studies vs. late studies. All sta-
tistical analyses were carried out using
STATA SE version 11.2/ (StataCorp LP,
4905 Lakeway Drive, College Station,
TX 77845, USA).
Results
A total of 39 studies were available, 20
in the early time-period (1997–2003)
(18–20,22–38) and 18 in the late time-
period (2004–2010) (16,21,27,39–53).
The results were analyzed according to
the evaluated clinical parameters,
namely CAL gain, probing pocket
depth reduction, BG as a percentage
and BG in mm.
Clinical attachment level
Ingeneral, therewasa significantoverall
increase in CAL [overall mean increase
in attachment level = 3.048 mm, 95%
confidence interval (95% CI) = 2.658–
3.437; p < 0.001]. This effect was not
significantlydifferentforearlystudiesvs.
late studies (p = 0.526). The mean in-
crease inCALfor the early studiesgroup
was 3.150 mm (95% CI = 2.585–
3.715 mm; p < 0.001) whereas for the
late studies group, the mean increase in
CALwas 2.937 mm (95%CI = 2.423–
3.450 mm; p < 0.001) (Fig. 1).
Probing pocket depth reduction
Similarly to the gains in CAL, there
was a significant overall reduction of
probing pocket depth; the overall
mean reduction of probing pocket
depth was 4.049 (95% CI = 3.659–
4.440; p < 0.001). This effect was not
significantly different between early
studies and late studies (p = 0.231).
The mean probing pocket depth
reduction for early studies was 4.223
mm (95% CI = 3.606–4.841 mm;
p < 0.001), whereas it was 3.845 mm
(95% CI = 3.516–4.175 mm; p <
0.001) for late studies (Fig. 2).
Bone gain (%)
When BG was examined as a percent-
age, a statistically significant increase of
43.024% (95% CI = 30.486–55.563%;
p < 0.001) was found. However, this
was not statistically significantly dif-
ferent between early studies and late
studies (p < 0.023). Mean BG was
36.212% (95% CI = 21.030–51.395%;
p < 0.001) for the early studies
and 59.292% (95% CI = 54.109–
64.474%, p < 0.001) for the late
studies. Nonetheless, these results
should be regarded with great care
because data were available from only
two studies in the early studies group
(Fig. 3).
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Heijl (18) 1997 2 3.2 36 2.6 Predominantly one to two
wall defects each, n = 17
34
Zetterstrom (37) 1997 2.9 3.7 31 2.4 Intraosseous defects N/A
about wall morphology
45
Sculean (20) 1999 3.2 5.7 0.9 Teeth scheduled for
extraction N/A
7



















Parodi (27) 2000 3.43 4.9 2.54 Angular bony defect
width ‡ 2 mm and
depth ‡ 3 mm
21
Bratthall (22) 2001 2.9 3.7 1 Intrabony defect width
‡ 2 mm and depth
‡ 3 mm
88
Pietruska (28) 2001 2.9 4.24 2.84 Defect depth ‡ 3 mm
Nine, 2-wall and three,
3-wall defects
25




Windisch (36) 2002 2.67 5 1.05 1-wall = 1
2-wall = 5
6
Pontoriero (29) 1999 2.9 4.4 Intrabony component
‡ 3 mm
10
Sculean (31) 1999 3 4.4 Intrabony defect
‡ 6 mm
32
Silvestri (32) 2000 4.5 4.8 Predominant 1- or
2-wall component
10




Tonetti (34) 2002 3.1 3.9 Intrabony defect
‡ 3 mm
83
Zuchelli (38) 2003 4.2 5.1 Angular bony defect
‡ 3 mm
30
Gutierez (23) 2003 1.4 2 N/A 20
Wachtel (35) 2003 3.6 3.9 Intrabony component
‡ 3 mm
1-, 2-, 3-wall defects
included
13
Silvestri (33) 2003 4.1 5.3 Intrabony component
‡ 4 mm
1-, 2-, 3-wall defects
included
6
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Bone gain (mm)
The last parameter evaluated was BG
expressed in mm. Once again, there was
an overall statistically significant BG of
2.35 mm (95% CI = 1.96–2.75 mm;
p < 0.001). Yet again, this was not sta-
tistically significant between early studies
and late studies (p = 0.449). Generally,
the early studies group had 2.191 mm
(95% CI = 1.530–2.851 mm; p <
0.001) of BG and the late studies group
had 2.49 mm (95% CI = 2.070–
2.91 mm; p < 0.001) of BG. (Fig. 4).
Discussion
EMD has been a subject of extensive
research, ranging from early investi-
gations to prove its efficacy (18,26,30)
to late investigations in combina-

















Vandana (53) 2004 3.13 4.5 1.4 Vertical bone loss on
X-ray
8




Francetti (42) 2004 4.29 4.86 57.4 3.44 Intrabony defect ‡ 4 mm
1-, 2-, 3-wall defects
12




Sipos (52) 2005 1.28 2.86 1.63 Radiographic depth
‡ 4 mm
12
Francetti (43) 2005 3.51 4.02 55 3.18 Intrabony defect ‡ 4 mm 83





Crea (41) 2008 2.5 3.5 58.8 2.4 Intrabony defect ‡ 4 mm 19
Grusovin & Esposito (44) 2009 3.3 3.9 2.5 Defect depth ‡ 4 mm
Defect width ‡ 2 mm
15
Sanz (16) 2004 3.1 3.8 Intbony defect ‡ 3 mm 35
Parodi (27) 2004 4.2 4.93 Angular osseous defects
‡ 3 mm
16
Rosing (49) 2005 2.01 4.17 Defect depth ‡ 3 mm
Defect width ‡ 2 mm
14
Sculean (51) 2005 3.9 4.5 Intrabony component





Bokan (39) 2006 3.7 3.9 Intraosseous component
‡ 3 mm
19
Chambrone (40) 2007 2.67 3.75 2+3-wall defects 13










Harrell (45) 2010 3.42 3.54 Sites with X-ray
bone loss N/A
13
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modalities (20,25,38,51). This meta-
analysis found that when EMD was
used in combination with flap surgery
for the treatment of intrabony defects,
a mean CAL gain of 3.04 mm and a
mean probing pocket depth reduction
of 4.05 mm could be obtained. This is
in agreement with the findings of
Klapidis & Ruben (54) in their meta-
analysis. Esposito et al. (55,56), in a
meta-analysis, evaluated CAL gains
obtained for EMD treatment
compared with open flap debridement,
but the effect was reduced by almost
half (1.1 mm vs. 0.62 mm) when only
studies were used that were at low risk
for bias. These findings are in contrast
to the results reported on CAL gains in
our investigation (3.09 mm) and might
be explained by a more stringent
exclusion of studies in Espositos
group. Another arm of the meta-anal-
ysis of Esposito et al. evaluated the
clinical outcomes of EMD vs. GTR
and reported no significant difference
between the two groups. However,
more postoperative complications and
recession occurred in the GTR-treated
sites. The authors acknowledged the
difficulty of the attempted comparisons
as a result of the great heterogeneity
between the study designs and the
outcomes reported (55,56).
Rathe et al. conducted a systematic
review evaluating the efficacy of EMD
for treating intrabony defects; they
concluded that EMD can be used pre-
dictably for regeneration of intrabony
defects, but found that EMDappears to
be more effective in well-contained de-
fects. Furthermore, the amount of bone
regeneration was less than achieved
with GTR (57). Generally our findings,
as far as can be compared, also suggest a
significant effectiveness of EMD in
NOTE: Weights are from random effects analysis
.
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Fig. 1. Random effects analysis of clinical attachment level (CAL) gain.
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intrabony defects, but the amount of
bone regeneration seems to be less pro-
nounced. A comparison between GTR
and EMD was not attempted in this
meta-analysis andwould be valuable for
a future comparison.
A benefit associated with the use of
EMD can be found when minimally
invasive surgical protocols are
employed and in esthetic areas
(45,58,59). These benefits relate to the
ease of application of EMDs. These
parameters were not included in the
present study design and would be of
great interest in future investigations.
Siciliano et al. (21) evaluated the per-
formance of EMD vs. GTR in deep,
noncontained defects and their results
were in favor of the GTR therapy.
Clinical application of the above-dis-
cussed findings indicates that EMD ex-
hibits potential for regeneration in well-
contained periodontal defects, to en-
hance wound healing and as an adjunct
to root coverage procedures combined
with Coronnally Advanced Flap. This
might be attributed to the effect ofEMD
in promoting early soft-tissue healing
and subsequent enhancement of wound
closure (17,60,61).
In addition, data from this meta-
analysis demonstrated a radiographic
BG of 43.02% and 2.35 mm when
EMD plus periodontal flap surgery
was used for the treatment of
intrabony defects. To the best of our
knowledge, no other published meta-
analysis has reported BG as a per-
centage or in mm.
NOTE: Weights are from random effects analysis
.
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Fig. 2. Random effects analysis of probing pocket depth reduction.
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When these findings were compared
with the available data from the An-
nals of Periodontology, the efficacy of
EMD appeared uncertain (2,3) as a
conventional periodontal flap proce-
dure can achieve a mean BG of 40–
50%, which is comparable with the
results reported for EMD in this meta-
analysis. One can assume that there
was minimal added benefit of EMD as
the percentage of BG was almost
identical to that achieved using the
conventional flap surgical procedure.
Nonetheless, the benefits of biologic
agents, such as EMD, cannot simply
be disregarded. Postoperative compli-
cations after GTR, for example mem-
brane exposure, have been reported to
occur in almost 75% of sites; however,
in the EMD group only 6% of sub-
jects experienced similar adverse
events (16). Lastly, the effect of EMD
on BG has been reported to be less
marked than with conventional GTR
(57).
To our knowledge, a comparison
between early studies (1997–2003) vs.
late studies (2004–2010) regarding the
treatment of periodontal intrabony
defects using EMD has not previously
been attempted. Comparison of early
studies with late studies identified no
statistically significant difference in the
efficacy of EMD determined using the
following clinical parameters: CAL,
probing pocket depth or BG (expressed
either as a percentage or in mm).
The limitations of this present
investigation are the limited sample
size, the timelines selected (which
could have been further divided into
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 93.4%, p = 0.000)





































Fig. 3. Random effects analysis of bone gain (BG) expressed as a percentage.
NOTE: Weights are from random effects analysis
.
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Fig. 4. Random effects analysis of bone gain (BG) expressed in mm.
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additional time intervals) and the sole
assessment of EMD. More studies are
needed to substantiate or refute the
reported results.
Conclusions
This meta-analysis failed to show any
significant differences between the
clinical results published in early or
later studies regarding the use of EMD
to treat periodontal intrabony defects.
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